Phua, J., Weng, L., Ling, L., Egi, M., Lim, C.M., Divatia, J.V., et al. (2020) Intensive Care Management of Coronavirus Disease 2019 (COVID-19): Challenges and Recommendations. The Lancet Respiratory Medicine, 8, 506-517.
https://doi.org/10.1016/S2213-2600(20)30161-2

has been cited by the following article:

• TITLE: Mitochondrial Organelle Transplantation Is a Potential Therapeutic for Mitochondria Dysfunction in Severe Acute Respiratory Syndrome (SARS) Coronavirus Diseases

  AUTHORS: Catherine C. Baucom, Xian-Peng Jiang

  KEYWORDS: COVID-19, Mitochondrial Dysfunction, Mitochondrial Organelle Transplantation, Lung Repair

  JOURNAL NAME: Advances in Infectious Diseases, Vol.11 No.3, September 16, 2021

  ABSTRACT: COVID-19 severe symptoms and high mortality are mainly seen in elders with age-associated diseases who have mitochondrial dysfunction. Mitochondrial dysfunction is a vulnerability and comorbidity of COVID-19. Cytokine storm, and increased serum iron and ferritin and reactive oxygen species (ROS) in COVID-19 further damage mitochondria. Amelioration of mitochondrial dysfunction may be a strategy of prevention and treatment of COVID-19. We also describe mitochondrial organelle transplantation (MOT) which has restored mitochondrial function, improved the repair of injured tissues and suppressed hyperinflammation in life-threatening sepsis. MOT is a potential therapy for severe COVID-19. Finally, we report the first case of MOT for a severe COVID-19 patient. MOT is safe and might have beneficial effect on the severe COVID-19.